Inherited Antithrombin III Deficiency: A Case Report of Familial Pedigree and Gene Mutation Screening

Rongrong Zhu,Zhanjiang Cao,Weiwei Wu
DOI: https://doi.org/10.1016/j.ejvs.2019.06.1011
IF: 6.427
2019-01-01
European Journal of Vascular and Endovascular Surgery
Abstract:Introduction - Inherited antithrombin III deficiency is an autosomal dominant genetic disease, which can lead to various forms of thrombus and is associated with pathological pregnancy. Methods - In this study, we reported a familial pedigree with three daughters diagnosed as AT III deficiency with different clinical manifestations. The first one was diagnosed with deep vein thrombus (DVT) during pregnancy and developed into acute pulmonary embolism (PE) under anticoagulation of low molecular heparin. The second one developed unprovoked DVT in left lower extremity and received the treatment of inferior vena filter, catheter-directed thrombolysis, pharmacomechanical thrombectomy and anticoagulation with rivaroxaban. The last one experienced an abortion because of placental abruption in the second trimester of pregnancy and the pathology indicated thrombosis in the microvessels of the placenta. We screened the whole family members for AT activity and antigen level, including the patients’ parents and sister without venous thromboembolism (VTE) history. Whole exome sequencing was performed in the first case to identify variations in the AT gene and Sanger sequencing was further adopted for other family members to verify the gene mutation responsible for the pedigree. We also conducted a long-term follow up of this family to help them with the anticoagulation during pregnancy and daily life. Results - Four members of the family, including the three sick daughters and their father, showed a deceased AT III activity and antigen level. However, their father did not have any VTE history before. The whole exome sequencing identified three nonsynonymous mutations, including c.1273C>T(p.R425C) mutation in SERPINC1, c.1200A>C(p.E400D) mutation in SERPINA1 and c.494C>T(p.T165M) mutation in F2. Then the Sanger sequencing for other family members verified the first mutation, c.1273C>T(p.R425C) mutation in SERPINC1, was the pathogenic gene for this family because of the consistence of mutation and decreased AT III activity. During the 2-year follow up, the father was attacked by DVT and two of the sick daughters gave birth to a healthy baby respectively with anticoagulation during pregnancy. Conclusion - Inherited antithrombin III deficiency is a hypercoagulable state associated with an increased risk for venous thrombosis, which cannot be relieved by low molecular heparin except NOACs like rivaroxaban. It is a disease with low incidence, few researches and no guidelines, so when and how to give anticoagulation remain controversial, especially during pregnancy. Further studies are necessary to give clues for clinical practicing of patients with this rare disease.
What problem does this paper attempt to address?